Payment overview · 2025
General Payments
$132.26
2 reported records · 2 companies
Healthcare provider profile · identity verified
Scott Alan Mccune, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTERSVILLE, NC · NPI 1407876675
Verified facts
What the public records show
CMS Open Payments records show Scott Alan Mccune, MD received $132.26 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 82.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $109.65 | 82.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.61 | 17.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $132.26 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $109.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 484 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 324 | 93 |
| Omeprazole | Omeprazole | 307 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 76 |
| Lisinopril | Lisinopril | 256 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 236 | 68 |
| Losartan Potassium | Losartan Potassium | 227 | 62 |
| Simvastatin | Simvastatin | 200 | 52 |
| Gabapentin | Gabapentin | 195 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 54 |
| Metformin Hcl Er | Metformin Hcl | 180 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 49 |
| Allopurinol | Allopurinol | 146 | 41 |
| Trazodone Hcl | Trazodone Hcl | 133 | 35 |
| Metformin Hcl | Metformin Hcl | 121 | 38 |
| Jardiance | Empagliflozin | 107 | 20 |
| Glimepiride | Glimepiride | 102 | 33 |
| Ezetimibe | Ezetimibe | 97 | 26 |
| Finasteride | Finasteride | 92 | 22 |
| Irbesartan | Irbesartan | 89 | 24 |
| Alprazolam | Alprazolam | 85 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 22 |
| Eliquis | Apixaban | 80 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 20 |
| Meloxicam | Meloxicam | 73 | 29 |
| Sertraline Hcl | Sertraline Hcl | 73 | 18 |
| Furosemide | Furosemide | 70 | 20 |
| Celecoxib | Celecoxib | 69 | 23 |
| Farxiga | Dapagliflozin Propanediol | 67 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 20 |
| Cefuroxime | Cefuroxime Axetil | 63 | 55 |
| Benazepril Hcl | Benazepril Hcl | 58 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 14 |
| Valsartan | Valsartan | 52 | 13 |
| Potassium Chloride | Potassium Chloride | 51 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 12 |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 21 |
| Prednisone | Prednisone | 45 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Carvedilol | Carvedilol | 43 | 13 |
| Montelukast Sodium | Montelukast Sodium | 42 | 14 |
| Synthroid | Levothyroxine Sodium | 42 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Atenolol | Atenolol | 36 | suppressed |
| Famotidine | Famotidine | 36 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 19 |
| Klor-Con M20 | Potassium Chloride | 33 | 11 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 22 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 14 |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $132.26 · 2 records | GlaxoSmithKline, LLC. | AREXVY, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error